Skip to Content

Xywav (calcium oxybate / magnesium oxybate / potassium oxybate / sodium oxybate) Disease Interactions

There are 6 disease interactions with Xywav (calcium oxybate / magnesium oxybate / potassium oxybate / sodium oxybate):

Major

Anxiolytics/sedatives/hypnotics (Includes Xywav) ↔ depression

Major Potential Hazard, Moderate plausibility. Applies to: Depression

A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics. Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations. These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation. Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders. Patients should be monitored for any changes in mood or behavior. It may be prudent to refrain from dispensing large quantities of medication to these patients.

References

  1. "Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical, Abbott Park, IL.
  2. "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.
  3. "Product Information. Equanil (meprobamate)." Wallace Laboratories, Cranbury, NJ.
  4. "Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca, Plattsburg, NY.
  5. "Product Information. Sonata (zaleplon)" Wyeth-Ayerst Laboratories, Philadelphia, PA.
View all 5 references
Major

Sodium oxybate (Includes Xywav) ↔ hx drug/alcohol abuse

Major Potential Hazard, Moderate plausibility. Applies to: Drug Abuse/Dependence, Alcoholism

Sodium oxybate should not be used with alcohol. This drug should be used with caution in patients with history of drug or alcohol abuse. The inappropriate use of this drug alone or in combination with other CNS depressants is associated with CNS adverse reaction including seizures, respiratory depression, decreases in the levels of consciousness, coma and death. Because illicit use and abuse has been reported, physicians should evaluate carefully their patients for history of drug or alcohol abuse and should follow such patients closely, observing them for signs of misuse.

Moderate

Anxiolytics/sedatives/hypnotics (Includes Xywav) ↔ glaucoma

Moderate Potential Hazard, Moderate plausibility. Applies to: Glaucoma/Intraocular Hypertension, Urinary Retention

Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.

Moderate

Anxiolytics/sedatives/hypnotics (Includes Xywav) ↔ liver disease

Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease

In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver. Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function. Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly. Laboratory testing is recommended prior and during treatment.

Moderate

Sodium oxybate (Includes Xywav) ↔ sensitivity to salt intake

Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction, Heart Disease, Hypertension, Hypertensive Heart (w/ CHF) and Renal Disease

Sodium oxybate has a high content of salt, and it should be used with caution in patients sensitive to salt intake such as patients with heart failure, hypertension, or renal impairment.

Moderate

Sodium oxybate (Includes Xywav) ↔ sleep apnea/respiratory depression

Moderate Potential Hazard, Moderate plausibility. Applies to: Sleep Apnea, Obesity, Narcolepsy

The use of sodium oxybate may impair the respiratory drive especially in patients with compromised respiratory function. Sodium oxybate should be used cautiously in patients with sleep apnea and sleep-related breathing disorders as there have been reports of increased central apneas and clinically relevant desaturation. Prescribers should be aware that sleep-related disorders tend to be more prevalent in obese patients, postmenopausal women not receiving hormone replacement therapy and also among patients with narcolepsy.

Xywav (calcium oxybate / magnesium oxybate / potassium oxybate / sodium oxybate) drug interactions

There are 331 drug interactions with Xywav (calcium oxybate / magnesium oxybate / potassium oxybate / sodium oxybate)

Xywav (calcium oxybate / magnesium oxybate / potassium oxybate / sodium oxybate) alcohol/food interactions

There are 3 alcohol/food interactions with Xywav (calcium oxybate / magnesium oxybate / potassium oxybate / sodium oxybate)

More about Xywav (calcium oxybate / magnesium oxybate / potassium oxybate / sodium oxybate)

Related treatment guides

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.